News
European Commission approves Nucula treatment in three diseases
GlaxoSmithKline (GSK) announced that the European Commission has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) for use in three additional eosinophil-driven diseases.